Cargando…

Human recombinant soluble ACE2 (hrsACE2) shows promise for treating severe COVID19

Detalles Bibliográficos
Autores principales:	Abd El-Aziz, Tarek Mohamed, Al-Sabi, Ahmed, Stockand, James D.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2020
Materias:	Research Highlight
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7607365/ https://www.ncbi.nlm.nih.gov/pubmed/33144565 http://dx.doi.org/10.1038/s41392-020-00374-6

Ejemplares similares

The ACE2 as a “rescue protein” or “suspect enzyme” in COVID-19: possible application of the “engineered inactive hrsACE2” as a safer therapeutic agent in the treatment of SARS-CoV-2 infection
por: Khodarahmi, Reza, et al.
Publicado: (2020)

SARS-CoV-2 infection of kidney organoids prevented with soluble human ACE2
por: Allison, Susan J.
Publicado: (2020)

ACE2 level as a marker of CVD
por: Fernández-Ruiz, Irene
Publicado: (2020)

Outsmarting SARS-CoV-2 by empowering a decoy ACE2
por: Sokolowska, Milena
Publicado: (2020)

Omicron: Master of immune evasion maintains robust ACE2 binding
por: Hoffmann, Markus, et al.
Publicado: (2022)

Human recombinant soluble ACE2 in severe COVID-19
por: Zoufaly, Alexander, et al.
Publicado: (2020)

A suspicious role of interferon in the pathogenesis of SARS-CoV-2 by enhancing expression of ACE2
por: Su, Shan, et al.
Publicado: (2020)

Blockade of SARS-CoV-2 infection by recombinant soluble ACE2
por: Alhenc-Gelas, Francois, et al.
Publicado: (2020)

ACE2 and Diabetes: ACE of ACEs?
por: Batlle, Daniel, et al.
Publicado: (2010)

Recombinant human ACE2: acing out angiotensin II in ARDS therapy
por: Zhang, Haibo, et al.
Publicado: (2017)

Engaging the spikes: heparan sulfate facilitates SARS-CoV-2 spike protein binding to ACE2 and potentiates viral infection
por: Kalra, Rajkumar Singh, et al.
Publicado: (2021)

SARS-CoV-2 infection in K18-ACE2 transgenic mice replicates human pulmonary disease in COVID-19
por: Arce, Victor M., et al.
Publicado: (2021)

mRNA vaccine shows promise in autoimmunity
por: Flemming, Alexandra
Publicado: (2021)

Soluble ACE2 in SARS-CoV-2 infection
por: Allison, Susan
Publicado: (2021)

Comparative docking studies to understand the binding affinity of nicotine with soluble ACE2 (sACE2)-SARS-CoV-2 complex over sACE2
por: C., Selvaa Kumar, et al.
Publicado: (2020)

Marine Brominated Tyrosine Alkaloids as Promising Inhibitors of SARS-CoV-2
por: El-Demerdash, Amr, et al.
Publicado: (2021)

Role of ACE, ACE2 and Neprilysin in the Kidney
por: Chappell, Mark C.
Publicado: (2007)

Engineered soluble ACE2 receptor: Responding to change with change
por: Li, Guangyao, et al.
Publicado: (2023)

Soluble ACE2 and TMPRSS2 Levels in the Serum of Asthmatic Patients
por: Lee, Ji-Hyang, et al.
Publicado: (2022)

ACE2, a promising therapeutic target for pulmonary hypertension
por: Shenoy, Vinayak, et al.
Publicado: (2011)

Angiotensin Converting Enzyme (ACE) and ACE2 Bind Integrins and ACE2 Regulates Integrin Signalling
por: Clarke, Nicola E., et al.
Publicado: (2012)

Expression of ACE2, Soluble ACE2, Angiotensin I, Angiotensin II and Angiotensin-(1-7) Is Modulated in COVID-19 Patients
por: Osman, Ikram Omar, et al.
Publicado: (2021)

Evidence in favor of the essentiality of human cell membrane-bound ACE2 and against soluble ACE2 for SARS-CoV-2 infectivity
por: Batlle, Daniel, et al.
Publicado: (2022)

Assessment of ACE1 variants and ACE1/ACE2 expression in COVID-19 patients
por: Akbari, Mohammadarian, et al.
Publicado: (2022)

Human Recombinant ACE2 Reduces the Progression of Diabetic Nephropathy
por: Oudit, Gavin Y., et al.
Publicado: (2010)

Not only ACE2—the quest for additional host cell mediators of SARS-CoV-2 infection: Neuropilin-1 (NRP1) as a novel SARS-CoV-2 host cell entry mediator implicated in COVID-19
por: Kyrou, Ioannis, et al.
Publicado: (2021)

Response to Evidence in favor of the essentiality of human cell membrane-bound ACE2 and against soluble ACE2 for SARS-CoV-2 infectivity
por: Yeung, Man Lung, et al.
Publicado: (2022)

ACE inhibitors on ACE1, ACE2, and TMPRSS2 expression and spheroid attachment on human endometrial Ishikawa cells
por: Fernando, Sudini R., et al.
Publicado: (2022)

Physical Activity and Inhibition of ACE Additively Modulate ACE/ACE-2 Balance in Heart Failure in Mice
por: Tyrankiewicz, Urszula, et al.
Publicado: (2021)

Killing Two Birds with One Stone by Administration of Soluble ACE2: A Promising Strategy to Treat Both Cardiovascular Diseases and SARS-CoV-2 Infection
por: Feng, Fengling, et al.
Publicado: (2021)

Angiotensin Converting Enzyme-2 (ACE-2) role in disease and future in research
por: Abdul-Hafez, Amal, et al.
Publicado: (2021)

Recent progress and challenges in drug development against COVID-19 coronavirus (SARS-CoV-2) - an update on the status
por: Abd El-Aziz, Tarek Mohamed, et al.
Publicado: (2020)

A bivalent recombinant vaccine: a promising strategy against both SARS-CoV-2 variants and wild type of the virus
por: Wang, Junzhi
Publicado: (2021)

The Two Faces of ACE2: The Role of ACE2 Receptor and Its Polymorphisms in Hypertension and COVID-19
por: Bosso, Mira, et al.
Publicado: (2020)

ACE2 localizes to the respiratory cilia and is not increased by ACE inhibitors or ARBs
por: Lee, Ivan T., et al.
Publicado: (2020)

Membrane-associated zinc peptidase families: comparing ACE and ACE2
por: Guy, J.L., et al.
Publicado: (2005)

Sex differences in the lung ACE/ACE2 balance in hypertensive rats
por: Martins, Flavia L., et al.
Publicado: (2021)

ACE and ACE2: insights from Drosophila and implications for COVID-19
por: Herrera, Paul, et al.
Publicado: (2021)

Clarifying the controversial risk-benefit profile of soluble ACE2 in COVID-19
por: Leow, Melvin Khee Shing
Publicado: (2020)

Allosteric binders of ACE2 are promising anti-SARS-CoV-2 agents
por: Hochuli, Joshua E., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_dk3jm2g5ms35iuc7gusn36s4hb